top of page
Excision Medical Catheter Excising Device Handle for valve stenosis repair
Excision Medical Logo White

The Natural Evolution of TAVR


Developing A Leaflet Modification System

Enabling Lifetime Management of Aortic Stenosis 


The Unmet Need

Aortic valve stenosis is the most common valvular heart disease in the developed world and the treatment of which is dominated by transcatheter aortic valve replacement (TAVR), representing a $5B market today. 

With the FDA approval of the low-risk patient group in recent years, TAVR valves are being implanted in younger and healthier patients each day further accelerating the growth of the market and treated patient population.  The ACC/AHA guidelines for patients with Structural Heart Disease were updated in 2020 and now state that any symptomatic patient over 65 years of age can be safely treated with either TAVR or surgery (Class I, LOE A).  We estimate that cumulatively, over 2 million US patients will be living with a bioprosthetic valve by 2032, with an increasing number of those patients outliving the lifespan of their implanted valve. 

When this occurs, there is a need to implant a new TAVR valve (‘redo’ TAVR) but this procedure is limited in application because of the many potential hazards the existing failed valve presents, such as acute obstruction of the coronary artery ostia.  Leaflet modification technology will be vital to mitigate procedural risks to enable patients to undergo the safest and most effective percutaneous treatment. 

Current methods to modify the leaflets before redo TAVR are complicated, time-consuming, and limited to simple leaflet laceration.  There are no commercially available methods for meaningful leaflet modification, what we refer to as ‘Leaflet Excision’, to excise the failed leaflets.  Leaflet excision technology will be vital to mitigate procedural risks to enable patients to undergo the safest and most effective percutaneous treatment in both the aortic and mitral positions.

The Device

The Excision Medical Leaflet Excision System is designed to allow physicians to target and excise one or more aortic valve leaflets while also considering the hemodynamic needs of patients.  Leaflet removal (or excision) will be key to properly mitigating the risk of coronary artery ostia obstruction, and debulking the existing valve prior to the redo TAVR, which may also offer additional benefits to the performance of the new valve.  


Excision Medical is setting the stage for fast and effective valve replacement by designing the system to integrate into the workflow of TAVR procedures as the wave of secondary replacement approaches in the coming years.  Leaflet Excision is the natural evolution of TAVR.

Stýri ™

Steering Catheters


RF Excision Catheter


Temporary Valve

The Procedure

A unique patent pending leaflet modification technology for lifetime management of aortic stenosis.

Warning: Excision Medical is a development stage company and the

Leaflet Excision system is not Approved by the FDA

Excision vs. Laceration

No Intervention


Large Excision

26mm CoreValve in 29mm CoreValve (with commissural alignment)

Management Team

Greg Walters

Co-Founder, President/CEO

Todd Sorzano

VP of Engineering

Jason Keiser

VP of Operations

Mike Dotsey

VP of Design

Chad Smith

VP of Product Development

Scientific Advisory Board

About Us

Press Releases

September 15th, 2022 - 


Contact Us

50 Three Tun Road


Malvern, PA, 19355

We look forward to talking to you soon!

sideview large.png
bottom of page